

## Position Paper

## Tobacco Use and the Periodontal Patient\*

This paper was prepared by the Research, Science and Therapy Committee of The American Academy of Periodontology and is intended for the information of the dental profession. The purpose of the paper is to provide the reader with a general overview of the relationship of tobacco use and periodontal diseases. This paper will review the epidemiological and clinical findings that have led to our understanding of the role of tobacco use in relation to periodontal diseases and their treatment. In addition, this paper will review the possible underlying mechanisms for these effects from tobacco use. The practitioner can use this information in treatment decisions and in giving advice to the patients who use tobacco products. *J Periodontol 1999;70:1419-1427.*

**T**obacco use is directly related to a variety of medical problems including cancer, low birth weight, and pulmonary and cardiovascular diseases.<sup>1</sup> In the past 25 years, there also has been an increasing awareness of the role of tobacco use in the prevalence and severity of periodontal diseases<sup>2</sup> and subsequent tooth loss.<sup>3-9</sup> Smoking appears to be one of the most significant risk factors in the development and progression of periodontal disease.<sup>10-16</sup> In the United States, where approximately 25% of the adult population smoke cigarettes,<sup>17</sup> and in other countries where the percentage of smokers may be higher,<sup>18,19</sup> this association between cigarette smoking and periodontal diseases represents a significant public health problem. Although the percentage of adults who smoke has declined in the United States since the 1970s,<sup>20</sup> the rate of decline is less among women and certain minorities,<sup>18-20</sup> and smoking has become more popular among youth. Smoking increased from 27.5% of United States high school students in 1991 to 36.4% in 1997. The use of smokeless tobacco products and cigars, particularly among young males, is another health concern.<sup>21</sup> The use of these tobacco products may also affect periodontal health.<sup>22-25</sup>

The potential impact of tobacco use on periodontal diseases will be discussed in 5 sections: 1) the effect of tobacco smoking on the prevalence and severity of periodontal diseases; 2) the effects of smoking on response to periodontal therapy; 3) mechanisms of periodontal disease progression in smokers; 4) the role of smokeless tobacco products, cigar and pipe smoking in periodontal diseases; and 5) periodontal effects of tobacco cessation.

\*This paper was developed under the direction of the Research, Science, and Therapy Committee and approved by the Board of Trustees of The American Academy of Periodontology in August 1999. It replaces the version published in January 1996.

### EFFECT OF TOBACCO SMOKING ON THE PREVALENCE AND SEVERITY OF PERIODONTAL DISEASES

An association between smoking and acute ulcerative gingivitis (ANUG) was demonstrated as early as 1946.<sup>26,27</sup> Epidemiological studies published in the 1980s and 1990s demonstrate an association between smoking and destructive periodontal disease. Results from the first United States National Health and Nutrition Examination Survey (NHANES I) demonstrated that although current smokers had more plaque and periodontal destruction than former or never smokers, the association between periodontal disease and smoking remained after adjusting for oral hygiene and other variables.<sup>28</sup>

In studies in which plaque accumulation was kept to a minimum or adjusted for in both smoking and non-smoking groups, the smoking groups had more sites with deeper pockets<sup>29-31</sup> and greater attachment loss.<sup>10,12,29,32</sup> Differences between current and never smokers in mean attachment level were highly significant and ranged from 0.37 mm among 35-year-olds to 1.33 mm in 75-year-old subjects.<sup>32</sup> A higher prevalence of furcation involvement among current as compared to never smokers has also been noted.<sup>32,33</sup> Compared to never smokers, almost twice as many current smokers had radiographic evidence of furcation involvement.<sup>33</sup> In addition, alveolar bone loss was greater in smokers.<sup>11,34,35</sup> In studies which have expressed alveolar bone height as a percentage of root length, the average bone height in current smokers was 77 to 78%, as compared to 83% in never smokers.<sup>34,35</sup> Similar findings have been reported from other large controlled cross-sectional population studies,<sup>23,36,37</sup> and in several longitudinal studies.<sup>16,24,25,38-40</sup> From these contemporary studies, a general pattern has emerged: smokers have greater attachment and bone loss, increased numbers

of deep pockets and calculus formation, but variable levels of plaque and inflammation, although the bias is towards decreased signs of clinical inflammation.

Depending upon the criteria used to define periodontal disease, smokers are 2.6 to 6 times more likely to exhibit periodontal destruction than non-smokers.<sup>10,12,39,41,42</sup> Regression analyses have shown that the relative risk of attachment loss among 25 to 74 year subjects with a history of moderate smoking (15 to 30 pack years) was 2.77; whereas, for current or former heavy smokers ( $\geq 30$  pack years), this figure was 4.75.<sup>10</sup> In the same population, the prevalence of severe bone loss, defined as bone level  $\geq 4$  mm apical to the cemento-enamel junction, was 4.7 times greater among current or former heavy smokers as compared to never smokers.<sup>11</sup>

Several studies have shown a relationship between the amount smoked and the prevalence and severity of periodontitis. A relationship has been demonstrated between the prevalence of moderate to severe periodontal disease and the number of cigarettes smoked per day<sup>2,9-11,37</sup> and to the number of years that the patient has smoked.<sup>9-11,41,43</sup> Attachment loss severity was increased by 0.5% by smoking 1 cigarette per day, while smoking up to 10 and 20 cigarettes a day increased attachment loss by 5% and 10%, respectively.<sup>37</sup> In the Erie County Study population, there was a strong positive relationship between bone loss and mean pack years of smoking; subjects with severe bone loss had a pack year history that was approximately 5 times that of subjects with normal bone levels.<sup>11</sup> Another investigation reported a positive correlation between serum levels of the nicotine metabolite, cotinine, and severity of clinical attachment loss, probing depth and alveolar crestal height in subjects aged 25 to 74 years.<sup>44</sup>

Studies which have focused on subjects less than 40 years of age have shown that smoking has a strong negative impact on periodontal status in young adults.<sup>2,29,45</sup> In one study,<sup>2</sup> current smokers in the 19 to 30 year age range were 3.8 times more likely to have periodontitis as compared to never smokers. Smokers with generalized early-onset periodontitis (G-EOP) had more affected teeth and more attachment loss than G-EOP patients who did not smoke. By contrast, attachment loss was not affected by smoking in younger patients with localized juvenile periodontitis (LJP).<sup>45</sup> It was suggested that the differential effects of smoking on G-EOP and LJP may be explained by the fact that the disease process responsible for attachment loss in LJP may not be of sufficient length to be influenced by smok-

ing. These studies demonstrate that smoking is strongly associated with periodontal destruction in young adults in their 20s and 30s.

Tobacco smoking probably plays a significant role in the development of refractory periodontitis.<sup>46-48</sup> An unusually high percentage of refractory patients are smokers (>90%)<sup>47,48</sup> when compared to the percentage of smokers in the general population (~25%).<sup>47</sup>

## EFFECT OF SMOKING ON THE RESPONSE TO PERIODONTAL THERAPY

Smoking has been identified as one of the major predictive variables for response to periodontal therapy.<sup>49,50</sup> In maintenance patients followed at least 5 years, patients who smoked were twice as likely to lose teeth.<sup>49</sup> The majority of studies involving non-surgical therapy have shown less probing depth reduction<sup>51-57</sup> and less attachment gain in smokers as compared to non-smokers.<sup>52,56</sup> Among patients who have been surgically treated for periodontitis and then longitudinally followed, smokers exhibited less reduction in probing depths,<sup>52,53,58</sup> less gain in clinical attachment levels,<sup>52,53</sup> and less gain in bone height<sup>59</sup> than non-smokers.

Root coverage following thick free gingival graft procedures is reportedly diminished by heavy cigarette smoking,<sup>60</sup> and there are conflicting reports on smoking's effect on the success of subepithelial connective tissue grafts.<sup>61,62</sup> Clinical attachment gains are also less in smokers as compared to non-smokers following regenerative procedures.<sup>63-67</sup> While the negative effects of smoking on therapy are evident from these studies, it must be remembered that periodontal therapy produced improvement of periodontal parameters in both smokers and nonsmokers.

Some studies have shown that implant success rates are reduced in smokers.<sup>68-71</sup> In one of these,<sup>69</sup> overall implant success rates up to 6 years among current smokers were approximately 89%, as compared to 95% in non-smokers. Other retrospective data did not identify smoking as a variable associated with implant failure.<sup>72,73</sup> A longitudinal study<sup>74</sup> has shown that marginal bone loss, albeit limited, was greater over a 15-year period around implants supporting mandibular fixed prosthesis in current smokers as compared to former or never smokers.

## MECHANISMS OF PERIODONTAL DISEASE PROGRESSION IN SMOKERS

### Microbiology

One hypothesis regarding the role of tobacco smoking in the development of periodontal diseases is that

when compared to non-smokers, smokers have more plaque or harbor different or more virulent types of plaque bacteria. However, some studies have shown that there is little difference in the level of plaque accumulation in smokers versus non-smokers.<sup>23,30,35</sup> In addition, in cross-sectional studies where plaque levels are controlled to minimum levels in current smokers and never smokers, the level of alveolar bone support is less in current smokers.<sup>35</sup>

Early studies using Gram-staining techniques and/or microscopic examination failed to show a significant difference in the subgingival microbial flora between smokers and non-smokers.<sup>75</sup> Other research reported no significant differences in the percentage recovery of periodontal pathogens from deep pockets between smokers and non-smokers.<sup>42,76</sup> However, cross-sectional data<sup>77</sup> from the large Erie County Study population demonstrated that the proportion of subjects positive for *Actinobacillus actinomycetemcomitans*, *Porphyromonas gingivalis*, and *Bacteroides forsythus* was significantly higher among current smokers as compared to never smokers. Current smokers were 3.1 times more likely to be infected with *A. actinomycetemcomitans* and 2.3 times more likely to be positive for *B. forsythus* than former or never smokers. Furthermore, the relative risk of *B. forsythus* infection increased as the amount of smoking increased; 43% of subjects smoking fewer than 10 cigarettes a day were *B. forsythus* positive as compared to 64% smoking more than 20 cigarettes a day.

A possible explanation for the diminished response to therapy in smokers could be due to differences in pathogen reductions. Some research<sup>78</sup> shows that there is no significant difference in the elimination of periodontal microflora following nonsurgical therapy in current smokers and never smokers, whereas other data<sup>54-57</sup> indicate that certain bacteria were more difficult to eradicate among current smokers. These included *A. actinomycetemcomitans*,<sup>54,57</sup> *P. gingivalis*,<sup>54,55</sup> and *B. forsythus*.<sup>55</sup>

#### **Effects on the Host Response and Periodontal Tissues**

Although bacteria are the primary etiologic factor in periodontal disease, the patient's host response is a determinant of disease susceptibility. In general, smoking could lead to increased periodontal destruction by altering the host response through 2 mechanisms: 1) impairment of the normal host response in neutralizing infection<sup>79</sup> and 2) alterations that result in destruction of the surrounding healthy periodontal tissues.<sup>80</sup>

Smokers appear to have depressed numbers of helper lymphocytes which are important to B cell function and antibody production.<sup>81-83</sup> This was manifested by decreased levels of salivary antibodies (IgA)<sup>84</sup> and serum IgG.<sup>81</sup> Other findings show that smoking is associated with diminished serum IgG2 levels both in white adults<sup>85</sup> and in black subjects with G-EOP.<sup>86</sup> Impaired IgG2 response has been hypothesized to increase the risk of periodontitis, however a cause and effect relationship between smoking and impaired IgG2 response has yet to be established.<sup>85</sup> Serum IgG antibodies to *Prevotella intermedia* and *Fusobacterium nucleatum* also have been reported to be reduced in smokers.<sup>87</sup>

In order for the host to deal efficiently with bacterial infections, fully functional neutrophils are required. It has been well documented that tobacco smoke and its individual components can have deleterious effects on various neutrophil functions.<sup>88-98</sup> For example, it has been shown that tobacco components can impair the chemotaxis and/or phagocytosis of both oral<sup>88,89</sup> and peripheral<sup>90,91</sup> neutrophils. Impairment of phagocytosis has also been reported in neutrophils from smokers with refractory periodontitis.<sup>47</sup> Smoking has been shown to stimulate or impair the oxidative burst of neutrophils.<sup>92-94</sup> In vitro nicotine exposure inhibits neutrophil production of superoxide anion and hydrogen peroxide, which are important to antimicrobial function.<sup>98</sup>

For many years, it has been hypothesized that smoking has a deleterious effect on gingival blood flow. The initial work<sup>99</sup> on the effects of nicotine demonstrated a decrease in gingival blood flow based on heat diffusion studies; however, later research using different methodology for smoke<sup>100</sup> or nicotine exposed tissues<sup>101</sup> yielded contradictory results. The medical literature has demonstrated that exposure to tobacco or nicotine impairs revascularization in soft<sup>102</sup> and hard tissues.<sup>103</sup> Similar phenomena may affect periodontal wound healing.

Nicotine can be stored in and released from periodontal fibroblasts.<sup>104</sup> However, it is unclear whether these fibroblasts exposed to nicotine have an impaired<sup>105</sup> or an enhanced ability<sup>106</sup> to attach to various surfaces. In addition, nicotine may inhibit fibroblast fibronectin and collagen production and increase fibroblast collagenase activity.<sup>107</sup> Nicotine can also suppress the proliferation of cultured osteoblasts while stimulating osteoblast alkaline phosphatase activity.<sup>108</sup>

Tobacco components may also modify the production of cytokines or inflammatory mediators

which play a role in periodontal tissue destruction. Nicotine has been shown to increase release of interleukin-6 by cultured murine osteoblasts.<sup>109</sup> Smokers have been reported to have increased crevicular fluid levels of tumor necrosis factor  $\alpha$ .<sup>59</sup> Nicotine has divergent effects on interleukin-1 and prostaglandin  $E_2$  secretion, depending upon the cell type and whether or not bacterial components are present.<sup>98,110-112</sup> Such alterations in host response may affect the reparative and regenerative potential of the periodontium in tobacco users.

## **ROLE OF SMOKELESS TOBACCO PRODUCTS AND CIGAR AND PIPE SMOKING IN PERIODONTAL DISEASES**

Smokeless tobacco products such as snuff and chewing tobacco are popular among young adults and in older women living in rural Southern areas in the United States.<sup>113-115</sup> The overall prevalence of current smokeless tobacco use among United States high school students is approximately 9%; however, 20.6% of white high school male students report current smokeless tobacco use.<sup>21</sup> The relationship of smokeless tobacco and oral carcinoma has been well documented.<sup>114</sup> Large-scale studies of athletes<sup>22,113</sup> and adolescents<sup>115-117</sup> who use smokeless tobacco have demonstrated a strong relationship to white oral mucosal lesions. These lesions are commonly found in areas of the mouth where smokeless tobacco products are placed and occur in 50 to 60% of smokeless tobacco users.<sup>22,118,119</sup>

A clear relationship between smokeless tobacco use and generalized periodontal conditions has not been definitively demonstrated.<sup>34</sup> In general, localized attachment loss in the form of gingival recession occurs in 25 to 30% of smokeless tobacco users.<sup>22,118,119</sup> This attachment loss is most prevalent adjacent to the mandibular buccal areas where smokeless tobacco products are commonly placed.<sup>22</sup> In vitro studies have demonstrated that smokeless tobacco extracts affect monocyte and oral keratinocyte production of inflammatory mediators which may play a role in the development of these localized tissue alterations.<sup>120-122</sup>

Between 1993 and 1997, overall cigar consumption in the United States increased almost 50%.<sup>123</sup> This may be due to emergence of cigar smoking among young affluent adults who tend to smoke premium cigars and the increased number of adults over the age of 50, which is a population believed to smoke more cigars than any other segment of our society.<sup>124</sup> The 1997 Youth Risk Behavior Survey<sup>21</sup>

reported that the overall prevalence of current cigar use, defined as at least 1 cigar smoked over the past 30 days, was 22%. Regular cigar smoking is associated with cancer of the oral cavity, lung, larynx, and esophagus.<sup>125</sup>

Relative to our knowledge of the effects of cigarettes and smokeless tobacco on the periodontium, there is less information regarding the periodontal effects of cigar and pipe smoking.<sup>23-25,28</sup> In general, a limitation of these studies is the relatively small sample size of cigar and pipe smokers available. In the NHANES I survey conducted between 1971 and 1974, periodontal index scores did not vary among pipe, cigar and cigarette smokers.<sup>28</sup>

The majority of data<sup>23-25</sup> on the periodontal effects of cigar and pipe smoking comes from the Veterans Administration Dental Longitudinal Study which began in 1968. At the baseline dental examination, 862 male subjects were classified as cigarette smokers, pipe/cigar smokers or non-smokers.<sup>23</sup> The latter category included former and never smokers. At the 6-year follow-up,<sup>24</sup> it was concluded that the periodontal status of the cigar/pipe group was intermediate between that of the cigarette and nonsmoking groups.

The most recent data from this cohort included 690 men who returned for examination at least once over a 23-year period.<sup>25</sup> Compared to non-smokers, smokers of cigars had a 1.3 fold risk of tooth loss, and pipe and cigarette smokers each had a 1.6 fold risk. Cigar and cigarette smokers also were at increased risk of experiencing alveolar bone loss compared to non-smokers. Unlike previous reports on this population, this study separated pipe and cigar smokers and included only men who smoked cigars, pipes, or cigarettes exclusively during the follow-up period. This factor, as well as the longer duration of follow-up, may explain this report's finding of a greater negative periodontal impact of cigar and pipe smoking as compared to the earlier studies.

## **PERIODONTAL EFFECTS OF TOBACCO CESSATION**

In general, the periodontal status of former smokers is intermediate between that of never smokers and current smokers.<sup>2,41,126</sup> These findings suggest that while the past effects of smoking on the periodontium cannot be reversed, smoking cessation is beneficial to periodontal health.

A previous history of smoking does not appear to be deleterious to the response of periodontal therapy.

Clinical studies comparing the response of current, former, and never smokers have reported that both never smokers and former smokers respond more favorably to therapy than current smokers and, furthermore, there was no significant difference between former and never smokers with respect to the efficacy of periodontal therapy.<sup>53,55</sup> Similarly, there was no association between number of years since smoking cessation and therapy response. This finding suggests that there is an early benefit of smoking cessation.<sup>55</sup> In a study of the effects of smoking cessation on implant failure, patients who quit smoking for 1 week before and 8 weeks after implant placement had significantly lower failure rates than patients who continued to smoke. Failure rates in these patients were not significantly different from non-smokers.<sup>127</sup> Collectively, these data are encouraging evidence for clinicians and their patients and emphasize the positive impact on smoking cessation on periodontal therapy response. For these reasons, the American Academy of Periodontology strongly recommends inclusion of tobacco cessation in periodontal therapy.<sup>128-130</sup>

The National Cancer Institute has developed tobacco-use intervention strategies for the dental setting.<sup>131,132</sup> Even minimal contact interventions have been shown to improve cessation rates over no-treatment conditions, although there is little doubt that longer person to person interactions have an even greater impact. The level of nicotine addiction, health status, training of the clinician, patient preference, and expense are all variables which affect selection of a particular intervention strategy.<sup>133</sup> When considering the detrimental effects of tobacco use on a variety of medical conditions,<sup>1</sup> smoking cessation advice given by the dentist may be beneficial to the smoking patient from a number of different health aspects. Tobacco cessation provides benefits by enhancing a patient's overall health as well as reducing their risk of periodontal disease and other oral pathologic alterations.

### SUMMARY

Clinical and epidemiological studies support the concept that tobacco use is an important variable affecting the prevalence and progression of periodontal diseases such as adult periodontitis, refractory periodontitis, generalized early-onset periodontitis, and ANUG. In studies in which plaque levels were adjusted between smokers and non-smokers, greater probing depths, clinical attachment loss, and bone loss have been reported in smokers. Several studies

have demonstrated that the severity of periodontal disease appears to be related to the duration of tobacco use, smoking status, and amount of daily tobacco intake. The majority of studies on the periodontal microflora of cigarette smokers show no difference between smokers and non-smokers, although recent studies involving large sample sizes suggest that certain periopathogens are more prevalent among smokers. Tobacco products appear to have direct local effects on periodontal tissue and can alter the host response. Smokeless tobacco use induces local clinical attachment loss at the site of intraoral placement, but is not associated with generalized periodontal destruction. Additional data are necessary before definitive conclusions can be drawn regarding the relationship between cigar smoking and periodontal disease. Although smokers benefit from periodontal therapy, clinical improvements are less than those for non-smoking patients. Studies comparing therapy response in former smokers, current smokers, and never smokers demonstrate that former smokers respond in a similar manner to never smokers to periodontal therapy. Based on this evidence, dental health professionals should advise patients of tobacco's negative health effects as well as the benefits of quitting tobacco use, and tobacco cessation counseling should be part of the armamentarium of the dental office.

### ACKNOWLEDGMENTS

The author of this position paper is Dr. Georgia K. Johnson. Members of the 1998-1999 Committee on Research, Science and Therapy include Drs. David L. Cochran, Chair; Timothy Blieden; Otis J. Bouwsma; Robert E. Cohen; Petros Damoulis; Connie Drisko; James B. Fine; William W. Hallmon; James E. Hinrichs; Martha J. Somerman; Gary Greenstein, Board Liaison; Vincent Iacono, Board Liaison; Robert J. Genco, Consultant; and Marjorie Jeffcoat, Technology Transfer Liaison.

### REFERENCES

1. Wald NJ, Hackshaw AK. Cigarette smoking: An epidemiological overview. *Br Med Bull* 1996;52:3-11.
2. Haber J, Wattles J, Crowley M, Mandell R, Joshipura K, Kent RL. Evidence for cigarette smoking as a major risk factor for periodontitis. *J Periodontol* 1993; 64:16-23.
3. Ahlqwist M, Bengtsson C, Hollender L, Lapidus L, Österberg T. Smoking habits and tooth loss in Swedish women. *Community Dent Oral Epidemiol* 1989;17:144-147.
4. Österberg T, Mellström D. Tobacco smoking: A major risk factor for loss of teeth in three 70-year-old cohorts. *Community Dent Oral Epidemiol* 1986;14:

- 367-370.
5. Holm G. Smoking as an additional risk for tooth loss. *J Periodontol* 1994;65:996-1001.
  6. Mohlin B, Ingervall B, Hedegård B, Thilander B. Tooth loss, prosthetics and dental treatment habits in a group of Swedish men. *Community Dent Oral Epidemiol* 1979;7:101-106.
  7. Ragnarsson E, Eliasson ST, Ólafsson SH. Tobacco smoking, a factor in tooth loss in Reykjavik, Iceland. *Scand J Dent Res* 1992;100:322-326.
  8. Jette AM, Feldman HA, Tennstedt SL. Tobacco use: A modifiable risk factor for dental disease among the elderly. *Am J Public Health* 1993;83:1271-1276.
  9. Krall EA, Dawson-Hughes B, Garvey AJ, Garcia RI. Smoking, smoking cessation and tooth loss. *J Dent Res* 1997;76:1653-1659.
  10. Grossi SG, Zambon JJ, Ho AW, et al. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. *J Periodontol* 1994;65:260-267.
  11. Grossi SG, Genco RJ, Machtei EE, et al. Assessment of risk for periodontal disease. II. Risk indicators for alveolar bone loss. *J Periodontol* 1995;66:23-29.
  12. Beck JD, Koch GG, Rozier RG, Tudor GE. Prevalence and risk indicators for periodontal attachment loss in a population of older community-dwelling blacks and whites. *J Periodontol* 1990;61:521-528.
  13. Ismail AI, Morrison EC, Burt BA, Caffesse RG, Kavanagh MT. Natural history of periodontal disease in adults: Findings from the Tecumseh periodontal disease study, 1959-1987. *J Dent Res* 1990;69:430-435.
  14. Horning GM, Hatch CL, Cohen ME. Risk indicators for periodontitis in a military treatment population. *J Periodontol* 1992;63:297-302.
  15. Locker D, Leake JL. Risk indicators and risk markers for periodontal disease experience in older adults living independently in Ontario, Canada. *J Dent Res* 1993;72:9-17.
  16. Beck JD, Koch CG, Offenbacher S. Incidence of attachment loss over 3 years in older adults—new and progressing lesions. *Community Dent Oral Epidemiol* 1995;23:291-296.
  17. Centers for Disease Control and Prevention. Cigarette smoking among adults. *MMWR* 1997;48:1217-1220.
  18. Bartecchi CE, MacKenzie TD, Schrier, RW. The human costs of tobacco use. I. *N Engl J Med* 1994;330:907-912.
  19. MacKenzie TD, Bartecchi CE, Schrier, RW. The human costs of tobacco use. II. *N Engl J Med* 1994;331:975-980.
  20. Garfinkel L. Trends in cigarette smoking in the United States. *Preventive Med* 1997;26:447-450.
  21. Centers for Disease Control. Tobacco use among high school students—United States. *MMWR* 1998;47:229-233.
  22. Robertson PB, Walsh M, Greene J, Ernster V, Grady D, Hauck W. Periodontal effects associated with the use of smokeless tobacco. *J Periodontol* 1990;61:438-443.
  23. Feldman RS, Bravacos JS, Rose CL. Associations between smoking, different tobacco products and periodontal disease indexes. *J Periodontol* 1983;54:481-487.
  24. Feldman RS, Alman JE, Chauncey HH. Periodontal disease indexes and tobacco smoking in healthy aging men. *Gerodontology* 1987;3:43-46.
  25. Krall EA, Garvey AJ, Garcia RI. Alveolar bone loss and tooth loss in male cigar and pipe smokers. *J Am Dent Assoc* 1999;130:57-64.
  26. Pindborg JJ. Tobacco and gingivitis. I. Statistical examination of the significance of tobacco in the development of ulceromembranous gingivitis and in the formation of calculus. *J Dent Res* 1947;26:261-264.
  27. Pindborg JJ. Tobacco and gingivitis. II. Correlation between consumption of tobacco, ulceromembranous gingivitis and calculus. *J Dent Res* 1949;28:460-463.
  28. Ismail AI, Burt BA, Eklund SA. Epidemiologic patterns of smoking and periodontal disease in the United States. *J Am Dent Assoc* 1983;106:617-621.
  29. Linden GJ, Mullally BH. Cigarette smoking and periodontal destruction in young adults. *J Periodontol* 1994;65:718-723.
  30. Bergström J, Eliasson S. Noxious effect of cigarette smoking on periodontal health. *J Periodont Res* 1987;22:513-517.
  31. Bergström J. Cigarette smoking as risk factor in chronic periodontal disease. *Community Dent Oral Epidemiol* 1989;17:245-247.
  32. Axelsson P, Paulander J, Lindhe J. Relationship between smoking and dental status in 35-, 50-, 65-, and 75-year-old individuals. *J Clin Periodontol* 1998;25:297-305.
  33. Mullally BH, Linden GJ. Molar furcation involvement associated with cigarette smoking in periodontal referrals. *J Clin Periodontol* 1996;23:658-661.
  34. Wouters FR, Salonen LWE, Frithiof L, Hellden LB. Significance of some variables on interproximal alveolar bone height based on cross-sectional epidemiologic data. *J Clin Periodontol* 1993;20:199-206.
  35. Bergström J, Eliasson S. Cigarette smoking and alveolar bone height in subjects with high standard of oral hygiene. *J Clin Periodontol* 1987;14:466-469.
  36. Anerud A, Løe H, Boysen H. The natural history and clinical course of calculus formation in man. *J Clin Periodontol* 1991;18:160-170.
  37. Martinez-Canut P, Lorca A, Magan R. Smoking and periodontal disease severity. *J Clin Periodontol* 1995;22:743-749.
  38. Bolin A, Lavstedt S, Frithiof L, Henrikson CO. Proximal alveolar bone loss in a longitudinal radiographic investigation. IV. Smoking and some other factors influencing the progress in individuals with at least 20 remaining teeth. *Acta Odontol Scand* 1986;44:263-269.
  39. Bergstrom J, Preber H. Tobacco use as a risk factor. *J Periodontol* 1994;65:545-550.
  40. Machtei EE, Dunford R, Hausmann E, et al. Longitudinal study of prognostic factors in established periodontitis patients. *J Clin Periodontol* 1997;24:102-109.
  41. Haber J, Kent RL. Cigarette smoking in periodontal practice. *J Periodontol* 1992;63:100-106.
  42. Stoltenberg JL, Osborn JB, Pihlstrom BL, et al.

- Association between cigarette smoking, bacterial pathogens, and periodontal status. *J Periodontol* 1993;64:1225-1230.
43. Alpagot T, Wolff LF, Smith QT, Tran SD. Risk indicators for periodontal disease in a racially diverse urban population. *J Clin Periodontol* 1996;23:982-988.
  44. Gonzalez YM, DeNardin A, Grossi SG, Machtei EE, Genco RJ, DeNardin E. Serum cotinine levels, smoking and periodontal attachment loss. *J Dent Res* 1996;75:796-802.
  45. Schenkein HA, Gunsolley JC, Koertge TE, Schenkein JG, Tew JG. Smoking and its effects on early-onset periodontitis. *J Am Dent Assoc* 1995;126:1107-1113.
  46. Adams DF. Diagnosis and treatment of refractory periodontitis. *Curr Opin Dent* 1992;2:33-38.
  47. MacFarlane GD, Herzberg MC, Wolff LF, Hardie NA. Refractory periodontitis associated with abnormal polymorphonuclear leukocyte phagocytosis and cigarette smoking. *J Periodontol* 1992;63:908-913.
  48. Magnusson I, Walker CB. Refractory periodontitis or recurrence of disease. *J Clin Periodontol* 1996; 23: 289-292.
  49. McGuire MK, Nunn ME. Prognosis versus actual outcome. III. The effectiveness of clinical parameters in accurately predicting tooth survival. *J Periodontol* 1996;67:666-674.
  50. Newman MG, Kornman KS, Holtzman S. Association of clinical risk factors with treatment outcomes. *J Periodontol* 1994;65:489-497.
  51. Preber H, Bergström J. The effect of non-surgical treatment on periodontal pockets in smokers and non-smokers. *J Clin Periodontol* 1986;13:319-323.
  52. Ah MKB, Johnson GK, Kaldahl WB, Patil KD, Kalkwarf KF. The effect of smoking on the response to periodontal therapy. *J Clin Periodontol* 1994; 21:91-97.
  53. Kaldahl WB, Johnson GK, Patil KD, Kalkwarf KL. Levels of cigarette consumption and response to periodontal therapy. *J Periodontol* 1996;67:675-681.
  54. Grossi SG, Skrepinski FB, DeCaro T, et al. Response to periodontal therapy in diabetics and smokers. *J Periodontol* 1996;67:1094-1102.
  55. Grossi SG, Zambon J, Machtei EE, et al. Effects of smoking and smoking cessation on healing after mechanical therapy. *J Am Dent Assoc* 1997;128: 599-607.
  56. Haffajee AD, Cugini MA, Dibart S, Smith C, Kent RL, Socransky SS. The effect of SRP on the clinical and microbiological parameters of periodontal diseases. *J Clin Periodontol* 1997;24:324-334.
  57. Renvert S, Dahlen G, Wikström M. The clinical and microbiological effects of non-surgical periodontal therapy in smokers and non-smokers. *J Clin Periodontol* 1998;25:153-157.
  58. Preber H, Bergström J. Effect of cigarette smoking on periodontal healing following surgical therapy. *J Clin Periodontol* 1990;17:324-328.
  59. Bostrom L, Linder LE, Bergstrom J. Influence of smoking on the outcome of periodontal surgery. A 5-year follow-up. *J Clin Periodontol* 1998;25:194-201.
  60. Miller PD. Root coverage with the free gingival graft. Factors associated with incomplete coverage. *J Periodontol* 1987;58:674-681.
  61. Harris RJ. The connective tissue with partial thickness double pedicle graft. The results of 100 consecutively-treated defects. *J Periodontol* 1994;65:448-461.
  62. Zucchelli G, Clauser C, De Sanctis M, Calandriello M. Mucogingival versus guided tissue regeneration procedures in the treatment of deep recession type defects. *J Periodontol* 1998;69:138-145.
  63. Rosen PS, Marks MH, Reynolds MA. Influence of smoking on long-term clinical results of intrabony defects treated with regenerative therapy. *J Periodontol* 1996;67:1159-1163.
  64. Tonetti MS, Pini-Prato G, Cortellini P. Effect of cigarette smoking on periodontal healing following GTR in infrabony defects. A preliminary retrospective study. *J Clin Periodontol* 1995;22:229-234.
  65. Trombelli L, Kim CK, Zimmerman GJ, Wikesjo UME. Retrospective analysis of factors related to clinical outcome of guided tissue regeneration procedures in intrabony defects. *J Clin Periodontol* 1997;24: 366-371.
  66. Luepke PG, Mellonig JT, Brunsvold MA. A clinical evaluation of a bioresorbable barrier with and without decalcified freeze-dried bone allograft in the treatment of molar furcations. *J Clin Periodontol* 1998;24:440-446.
  67. Cortellini P, Pini Prato GP, Tonetti MS. Long-term stability of clinical attachment following guided tissue regeneration and conventional therapy. *J Clin Periodontol* 1996;23:106-111.
  68. Jones JK, Triplett RG. The relationship of cigarette smoking to impaired intraoral wound healing: A review of evidence and implications for patient care. *J Oral Maxillofac Surg* 1992;50:237-239.
  69. Bain CA, Moy PK. The association between the failure of dental implants and cigarette smoking. *Int J Oral Maxillofac Implants* 1993;8:609-615.
  70. De Bruyn H, Collaert B. The effect of smoking on early implant failure. *Clin Oral Implants Res* 1994;5:260-264.
  71. Gorman LM, Lambert PM, Morris HF, Ochi S, Winkler S. The effect of smoking on implant survival at second stage surgery: DICRG interim report No. 5. Dental implant clinical research group. *Implant Dent* 1994;3:165-168.
  72. Minsk L, Polson AM, Weisgold A, et al. Outcome failures of endosseous implants from a clinical training center. *Compend Continuing Educ Dent* 1996;17:848-859.
  73. Weyant RJ. Characteristics associated with the loss and peri-implant tissue health of endosseous dental implants. *Int J Oral Maxillofac Implants* 1994;9: 95-102.
  74. Lindquist LW, Carlsson GE, Jemt T. A prospective 15-year follow-up study of mandibular fixed prostheses supported by osseointegrated implants. Clinical results and marginal bone loss. *Clin Oral Implants Res* 1996;7:329-336.
  75. Kenney EB, Saxe SR, Bowles RD. The effect of cigarette smoking on anaerobiosis in the oral cavity. *J Periodontol* 1975;46:82-85.
  76. Preber H, Bergström J, Linder LE. Occurrence of periopathogens in smoker and non-smoker patients.

- J Clin Periodontol* 1992;19:667-671.
77. Zambon JJ, Grossi SG, Machtei EE, Ho AW, Dunford R, Genco RJ. Cigarette smoking increases the risk for subgingival infection with periodontal pathogens. *J Periodontol* 1996;67:1050-1054.
  78. Preber H, Linder L, Bergstrom J. Periodontal healing and periopathogenic microflora in smokers and nonsmokers. *J Clin Periodontol* 1995;22:946-952.
  79. Seymour GJ. Importance of the host response in the periodontium. *J Clin Periodontol* 1991;18:421-426.
  80. Lamster IB. The host response in gingival crevicular fluid: Potential applications in periodontitis clinical trials. *J Periodontol* 1992;63:1117-1123.
  81. Barbour SE, Nakashim K, Zhang JB, et al. Tobacco and smoking: Environmental factors that modify the host response (immune system) and have an impact on periodontal health. *Crit Rev Oral Biol Med* 1997;8:437-460.
  82. Costabel U, Bross KJ, Reuter C, Rühle KH, Matthys H. Alterations in immunoregulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes. *Chest* 1986;90:39-44.
  83. Ginns LC, Goldenheim PD, Miller LG. T-lymphocyte subsets in smoking and lung cancer. Analyses of monoclonal antibodies and flow cytometry. *Am Rev Respir Dis* 1982;126:265-269.
  84. Bennet KR, Read PC. Salivary immunoglobulin A levels in normal subjects, tobacco smokers, and patients with minor aphthous ulceration. *Oral Surg Oral Med Oral Pathol* 1982;53:461-465.
  85. Quinn SM, Zhang JB, Gunsolley JC, Schenkein HA, Tew JG. The influence of smoking and race on adult periodontitis and serum IgG2 levels. *J Periodontol* 1998;69:171-177.
  86. Tangada SD, Califano JV, Nakashima K, et al. The effect of smoking on serum IgG2 reactive with *Actinobacillus actinomycetemcomitans* in early-onset periodontitis patients. *J Periodontol* 1997;68:842-850.
  87. Haber J. Cigarette smoking: A major risk factor for periodontitis. *Compend Continuing Educ Dent* 1994; 15:1002-1014.
  88. Kenney EB, Kraal JH, Saxe SR, Jones J. The effect of cigarette smoke on human oral polymorphonuclear leukocytes. *J Periodont Res* 1977;12:227-234.
  89. Eichel B, Shahrik HA. Tobacco smoke toxicity: Loss of human oral leukocyte function and fluid cell metabolism. *Science* 1969;166:1424-1428.
  90. Lannan S, McLean A, Drost E, et al. Changes in neutrophil morphology and morphometry following exposure to cigarette smoke. *Int J Exp Pathol* 1992;73:183-191.
  91. Selby C, Drost E, Brown D, Howie S, MacNee W. Inhibition of neutrophil adherence and movement by acute cigarette smoke exposure. *Exp Lung Res* 1992; 18:813-827.
  92. Kalra J, Chandhary AK, Prasad K. Increased production of oxygen free radicals in cigarette smokers. *Int J Exp Pathol* 1991;72:1-7.
  93. Codd EE, Swim AT, Bridges RB. Tobacco smokers' neutrophils are desensitized to chemotactic peptide-stimulated oxygen uptake. *J Lab Clin Med* 1987; 110:648-652.
  94. Ryder MI, Fujitaki R, Johnson G, Hyun W. Alterations of neutrophil oxidative burst by in vitro smoke exposure: Implications for oral and systemic diseases. *Ann Periodontol* 1998;3:76-87.
  95. Nowak D, Ruta U, Piasecka G. Nicotine increases human polymorphonuclear leukocytes chemotactic response—a possible additional mechanism of lung injury in cigarette smokers. *Exp Pathol* 1990;39: 37-43.
  96. Totti N, McCusker KT, Campbell EJ, Griffin GL, Senior RM. Nicotine is chemotactic for neutrophils and enhances neutrophil responsiveness to chemotactic peptides. *Science* 1984;227:169-171.
  97. Ryder MI. Nicotine effects on neutrophil F-actin formation and calcium release: Implications for tobacco use and pulmonary diseases. *Exp Lung Res* 1994;20:283-296.
  98. Pabst MJ, Pabst KM, Collier JA, et al. Inhibition of neutrophil and monocyte defensive functions by nicotine. *J Periodontol* 1995;66:1047-1055.
  99. Clarke NG, Shephard BC, Hirsch RS. The effects of intra-arterial epinephrine and nicotine on gingival circulation. *Oral Surg Oral Med Oral Pathol* 1981;52:577-582.
  100. Baab DA, Oberg PA. The effect of cigarette smoking on gingival flow in humans. *J Clin Periodontol* 1987;14:418-424.
  101. Johnson GK, Todd GL, Johnson WT, Fung YK, Dubois LM. Effects of topical and systemic nicotine on gingival blood flow in dogs. *J Dent Res* 1991;70: 906-909.
  102. Mosely LH, Finseth F, Goody M. Nicotine and its effects on wound healing. *Plast Reconstr Surg* 1978; 61:570-575.
  103. Riebel GD, Boden SD, Whitesides TE, Hutton WC. The effect of nicotine on incorporation of cancellous bone graft in an animal model. *Spine* 1995;20:2198-2202.
  104. Hanes PJ, Schuster GS, Lubas S. Binding, uptake, and release of nicotine by human gingival fibroblasts. *J Periodontol* 1991;62:147-152.
  105. Raulin LA, McPherson JC, McQuade MJ, Hanson BS. The effect of nicotine on the attachment of human fibroblasts to glass and human root surfaces in vitro. *J Periodontol* 1989;59:318-325.
  106. Peacock ME, Sutherland DE, Schuster GS, et al. The effect of nicotine on reproduction and attachment of human gingival fibroblasts in vitro. *J Periodontol* 1993;64:658-665.
  107. Tipton DA, Dabbous MK. Effects of nicotine on proliferation and extracellular matrix production of human gingival fibroblasts in vitro. *J Periodontol* 1995;66:1056-1064.
  108. Fang MA, Frost PJ, Iida-Klein A, Hahn TJ. Effects of nicotine on cellular function in UMR 106-01 osteoblast-like cells. *Bone* 1991;12:283-286.
  109. El-Ghorab N, Marzec N, Genco R, Dziak R. Effect of nicotine and estrogen on IL-6 release from osteoblasts. *J Dent Res* 1997;76(Spec. Issue):341(Abstr. 2619).
  110. Payne JB, Johnson GK, Reinhardt RA, Dyer JK, Maze CA, Dunning DG. Nicotine effects on PGE2 and IL-1 $\beta$  release by LPS-treated human monocytes.



- J Periodont Res* 1996;31:99-104.
111. Johnson GK, Organ CC. Prostaglandin E<sub>2</sub> and interleukin-1 levels in nicotine-exposed oral keratinocyte cultures. *J Periodont Res* 1997;32:447-454.
  112. Seow WK, Thong YH, Nelson RD, MacFarlane GD, Herzberg MC. Nicotine-induced release of elastase and eicosanoids by human neutrophils. *Inflammation* 1994;18:119-127.
  113. Ernster VL, Grady DG, Greene JC, et al. Smokeless tobacco use and health effects among baseball players. *JAMA* 1990;264:218-224.
  114. Wray A, McQuirt WF. Smokeless tobacco usage associated with oral carcinoma. Incidence, treatment, outcome. *Arch Otolaryngol Head Neck Surg* 1993; 119:929-933.
  115. Creath CJ, Cutter G, Bradley DH, Wright JT. Oral leukoplakia and adolescent smokeless tobacco use. *Oral Surg Oral Med Oral Pathol* 1991;72:35-41.
  116. Tomar SL, Winn DM, Swango PA, Giovino GA, Kleinman DV. Oral mucosal smokeless tobacco lesions among adolescents in the United States. *J Dent Res* 1997;76:1277-1286.
  117. Offenbacher S, Weathers DR. Effects of smokeless tobacco on the periodontal, mucosal and caries status of adolescent males. *J Oral Pathol* 1985; 14:169-181.
  118. Greer RO Jr, Poulson TC. Oral tissue alterations associated with the use of smokeless tobacco by teen-agers, Part I. Clinical findings. *Oral Surg Oral Med Oral Pathol* 1983; 56:275-84.
  119. Poulson TC, Lindenmuth JE, Greer RO Jr. A comparison of the use of smokeless tobacco in rural and urban teenagers. *CA Cancer J Clin* 1984;34: 248-61.
  120. Payne JB, Johnson GK, Reinhardt RA, Maze CR, Dyer JK, Patil KD. Smokeless tobacco effects on monocyte secretion of PGE<sub>2</sub> and IL-1 $\beta$ . *J Periodontol* 1994;65:937-941.
  121. Johnson GK, Poore TK, Payne JB, Organ CC. Effect of smokeless tobacco extract on human gingival keratinocyte levels of prostaglandin E<sub>2</sub> and interleukin-1. *J Periodontol* 1996;67:116-124.
  122. Bernzweig E, Payne JB, Reinhardt RA, Dyer JK, Patil KD. Nicotine and smokeless tobacco effects on gingival and peripheral blood mononuclear cells. *J Clin Periodontol* 1998;25:246-252.
  123. US Department of Agriculture. *Tobacco Situation and Outlook Report*. TBS-237. Washington, DC: US Department of Agriculture, Commodity Economics Division, Economic Research Service; 1996.
  124. Slade J. Marketing and promotion of cigars. In: Burns D, Cummings KM, Hoffmann D, eds. *Cigars: Health Effects and Trends. Smoking and Tobacco Control Monograph 9*. USDHHS NIH NCI. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 1998:195-200.
  125. Shanks TG, Burns DM. Disease consequences of cigar smoking. In: Burns D, Cummings KM, Hoffmann D, eds. *Cigars: Health Effects and Trends. Smoking and Tobacco Control Monograph 9*. USDHHS NIH NCI. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 1998:105-190.
  126. Bolin A, Eklund G, Frithiof L, Lavstedt S. The effect of changed smoking habits on marginal alveolar bone loss. *Swed Dent J* 1993;17:211-216.
  127. Bain CA. Smoking and implant failure—Benefits of a smoking cessation protocol. *Int J Oral Maxillofac Implants* 1996;11:756-759.
  128. The American Academy of Periodontology. Parameter on adult periodontitis with slight to moderate loss of periodontal support. *Parameters of Care*. Chicago: American Academy of Periodontology 1996:11.
  129. The American Academy of Periodontology. Parameter on adult periodontitis with advanced loss of periodontal support. *Parameters of Care*. Chicago: American Academy of Periodontology 1996:17.
  130. The American Academy of Periodontology. Parameter on refractory periodontitis. *Parameters of Care*. Chicago: American Academy of Periodontology 1996:25.
  131. Christen AG, Klein JA, Christen JA, McDonald JL Jr, Guba CJ. How-to-do-it quit-smoking strategies for the dental office team: An eight-step program. *J Am Dent Assoc* 1990;Jan Supplement:20S-27S.
  132. Mecklenburg RE, Christen AG, Gerbert B, Gift MC et al. How to help your patients stop using tobacco: A National Cancer Institute manual for the oral health team. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1991. NIH publication no. 91-3191.
  133. Anonymous. Smoking cessation: Information for specialists. Agency for Health Care Policy and Research. Clinical Practice Guideline—Quick Reference Guide for Clinicians. 1996;(18B):1-10.

Individual copies of this position paper may be obtained by contacting the Scientific, Clinical and Educational Affairs Department at The American Academy of Periodontology, Suite 800, 737 North Michigan Avenue, Chicago, Illinois 60611-2690; voice: 312/573-3230; fax: 312/573-3234; e-mail: [adriana@perio.org](mailto:adriana@perio.org). Members of The American Academy of Periodontology have permission of the Academy, as copyright holder, to reproduce 150 copies of this document for not-for-profit educational purposes only. For information on reproduction of this document for any other use or distribution, please contact Rita Shafer at the Academy Central Office; voice: 312/573-3221; fax: 312/573-3225; or e-mail: [rita@perio.org](mailto:rita@perio.org).